Attorney Docket No.:

SYM114 (TI-0029)

Inventors:

• Pei et al.

Serial No.: Filing Date:

09/882,843 June 15, 2001

Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1: (currently amended) A compound of Formula I:

wherein

 R^1 , R^2 , R^3 and R^4 are independently

H,

HO,

R130-,

R13S.

Halogen halogen,

C1-C3-alkyl,

```
Attorney Docket No.: SYM114 (TI-0029)
 Inventors:
                                      Pei et al.
 Serial No.:
                                     09/882,843
 Filing Date:
                                     June 15, 2001
 Page 3
                CF3,
               R^{14}CO_2-,
               R14O2C-,
               R14CO-
               R14CONH-,
               R¹⁴NHCO-,
               R^{14}NHCO_2-
               R14OCONH-,
               R14025-,
               R14OS-,
               RTS-, or
               R15R16N-; or
       \mbox{R}^{1} and \mbox{R}^{2}, or \mbox{R}^{2} and \mbox{R}^{3}, or \mbox{R}^{3} and \mbox{R}^{4} taken together can be
               -SCH<sub>2</sub>S-,
               -SCH<sub>2</sub>Q-,
               -OCH<sub>2</sub>S-,
               -SCH<sub>2</sub>CH<sub>2</sub>S-,
               -SCH<sub>2</sub>CH<sub>2</sub>O-, or
               -OCH<sub>2</sub>CH<sub>2</sub>S-;
wherein one of R^1, R^2, R^3 and R^4 must be C1-C3-alkoxy or C1-C3-
alkylthio group;
       R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently
```

```
Attorney Docket No.: SYM114 (TI-0029)
                               Pei et al.
Inventors:
                               09/882,843
Serial No.:
Filing Date:
                               June 15, 2001
Page 4
             Η,
             C1-C6-alkyl,
             C3-C6-alkenyl,
             C3-C6-cycloalkyl,
             phenyl or substituted phenyl, wherein the phenyl is
substituted with one or two substituents, C1-C3-alkyl, halogen,
R^{13}O_{-}, CF_{3-}, R^{14}O_{2}S_{-}, R^{14}OS_{-}, R^{14}CO_{2}, R^{14}O_{2}C_{-}, R^{14}CONH_{-}, R^{14}NHCO_{2}
or
      R<sup>5</sup> and R<sup>6</sup> taken together can be C3-C6-cycloalkyl;
      R' and R' taken together can be C3-C6-cycloalkyl;
      R<sup>9</sup> is
             R15R16NCO-,
             R15R16NCS-,
             R^{15}R^{16}N(CR^{17}) - .
             R170CO-,
             R15CO-,
             R<sup>15</sup>R<sup>16</sup>NCH<sub>2</sub>CO-,
             R^{14}O_2C-(CH_2)_n-,
             R^{15}R^{16}NCO - (CH_2)_{n} - ,
             NC- (CH<sub>2</sub>) n-,
             Η,
             C1-C6-alkyl,
```

```
Attorney Docket No.: SYM114 (TI-0029)
                                  Pei et al.
Inventors:
                                   09/882,843
Serial No.:
                                   June 15, 2001
Filing Date:
Page 5
              C3-C6-alkenyl, or
              C3-C6-cycloalkyl; or
       R<sup>0</sup> and R<sup>9</sup> taken together can be
              - (CH<sub>2</sub>) mCH<sub>2</sub> (R<sup>15</sup>) NCO-,
              -(CH<sub>2</sub>) mCH<sub>2</sub>OCO-, or
              - (CH<sub>2</sub>) mCH<sub>2</sub>CH<sub>2</sub>CO-;
       R10 and R11 are independently
              Η,
              R^{15}R^{16}N-,
              R^{15}R^{16}N(CR^{17}) -,
              R14HNCO-, or
              R14CONH-;
       R^{12} is
               Η,
              Halogen halogen,
            . HO,
               R130-,
               R15R16N-,
               C1-C3-alkyl,
               CF,
               R^{14}CO_2-,
               R14CO-, or
```

Attorney Docket No.: SYM114 (TI-0029)

Inventors: Serial No.: Filing Date:

Pei et al. 09/882,843 June 15, 2001

Page 6

R14CONH-;

R¹³ is C1-C3-alkyl;

R14 is H or C1-C3-alkyl;

R15 and R16 are independently

Η,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10, alkenyl, or

C3-C6-cycloalkyl; or

R15 and R16 taken together can be C3-C6-cycloalkyl;

R¹⁷ is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R10 and R11 cannot be both H.

Claim 2: (currently amended) The compound of claim 1 of Formula I wherein one of four the substituents of R^1 , R^2 , R^3 and R^4 must be Cl-C3-alkylthic group or Cl-C3-alkoxy group, the other substituents are independently H, R130-, R13S-, halogen, or C1-C3-alkyl;

 R^2 and R^3 taken together can be -SCH₂S-, SCH₂O-, or -OCH₂S-;

```
SYM114 (TI-0029)
Attorney Docket No.:
                               Pei et al.
Inventors:
Serial No.:
                                09/882,843
                                June 15, 2001
Filing Date:
Page 7
R9 is
      R15R16NCO-,
      R15R16NCS-,
      R^{15}R^{16}N(CR^{17}) - .
      R170CO-, or
      R15CO-<u>, or</u>
      H: .
R<sup>10</sup> and R<sup>11</sup> are independently H, H<sub>2</sub>N-, or CH<sub>3</sub>CONH-; and
pharmaceutically acceptable salts thereof.
```

Claim 3: (previously amended) A composition comprising the

compound of claim 2 and a pharmaceutically acceptable carrier.

Claim 4: (canceled)

Claim 5: (currently amended) The compound of claim 2 claim 1 of

Formula I selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy
5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl
3-methylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1
(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl
7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-

Attorney Docket No.: SYM114 (TI-0029)
Inventors: Pei et al.
Serial No.: 09/882,843
Filing Date: June 15, 2001

Page 8

methyl-3-propylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5H -2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3propylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4methyl-3-acetyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3methylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5 -dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino -3,5-dihydro-4methyl-3-acetyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4Attorney Docket No.: SYM114 (TI-0029)
Inventors: Pei et al.
Serial No.: 09/882,843
Filing Date: June 15, 2001
Page 9

Aminophenyl) -7-amino-3,5-dihydro-4-methyl-3-methylcarbomyl-8methoxy-5H-2,3-benzodiazepine, 1-(4-aminophenyl)-7-amino-3,5dihydro-4-methyl-3-ethylcarbomoyl-8-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3propylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -7-amino-3,5-dihydro-4-methyl-3-butylcarbamnoyl-8methoxy-5H-2,3-benzodiazepine, 1-(4- Aminophenyl)-3,5-dihydro -4-methyl-3-acetyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl -7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-51H-2,3benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5#-2,3benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3methylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4- methyl-3-ethylcarbamoyl -7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3 ,5-dihydro-4-methyl-3-propylcarbamoyl-7-methvlthio-5H-2,3Attorney Docket No.;

SYM114 (TI-0029)

Inventors: Serial No.: Pei et al. 09/882,843

Filing Date:

June 15, 2001

Page 10

benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4methyl-3-butylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1 -(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5H-2, 3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3methylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoy1-8-methylthiio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4methyl-3-acetyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3propylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, and 1-(4-Aminophenyl) -7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8methylthio-5H-2,3-benzodiazepine.

Claim 6: (previously amended) A composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

Attorney Docket No.:

SYM114 (TI-0029)

Inventors:
Serial No.:
Filing Date:

Pei et al. 09/882,843 June 15, 2001

Page 11

Claim 7: (canceled)

Claim 8: (previously amended) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 9: (canceled)

Claim 10: (currently amended) A method for treating a patient having a disorder associated with excessive activation of the amino-3-hydroxy-5-methyl-4-isooxazoleproprionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors suffering from ischemia, epilepsy or stroke, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder ischemia, epilepsy or stroke, a compound of Formula I:

Attorney Docket No.:

SYM114 (TI-0029)

Inventors: Serial No.: Filing Date: Pei et al. 09/882,843 June 15, 2001

Page 12

wherein

R1, R2, R3 and R4 are independently

Н,

HO,

R130-,

R¹³S-.

Halogen halogen,

C1-C3-alkyl,

CF₃,

R14CO2-,

R14O2C-,

Η,

Cl-C6-alkyl,

C3-C6-alkenyl,

```
Attorney Docket No.: SYM114 (TI-0029)
                            Pei et al.
Inventors:
Serial No.:
                             09/882,843
                            June 15, 2001
Filing Date:
Page 14
        C3-C6-cycloalkyl,
        phenyl or substituted phenyl, wherein the phenyl is
substituted with one or two substituents, C1-C3-alkyl, halogen,
R^{13}O-, CF_3-, R^{14}O_2S-, R^{14}OS-, R^{14}CO, R^{14}CO_2-, R^{14}O_2C-, R^{14}CONH-, R^{14}NHCO;
or
      R5 and R6 taken together can be C3-C6-cycloalkyl;
      R7 and R8 taken together can be C3-C6-cycloalkyl;
      R<sup>9</sup> is
         R15R16NCO-,
         R15R16NCS-,
         R^{15}R^{16}N(CR^{17}) - ,
         R170CO-,
         R15CO-,
         R^{15}R^{16}NCH_2CO-,
         R^{14}O_2C - (CH_2)_n - ,
         R^{15}R^{16}NCO-(CH_2)_n-,
         NC-(CH_2)n-
         Η,
         C1-C6-alkyl,
        .C3-C6-alkenyl, or
         C3-C6-cycloalkyl; or
      R<sup>8</sup> and R<sup>9</sup> taken together can be
```

```
Attorney Docket No.: SYM114 (TI-0029)
Inventors:
                                Pei et al.
Serial No.:
                                 09/882,843
Filing Date:
                                June 15, 2001
Page 15
         - (CH<sub>2</sub>) mCH<sub>2</sub> (R<sup>15</sup>) NCO-,
         -(CH<sub>2</sub>)mCH_2OCO-, or
         - (CH<sub>2</sub>) mCH<sub>2</sub>CH<sub>2</sub>CO-,;
      R10 and R11 are independently
         Η,
         R^{15}R^{16}N-,
         R^{15}R^{16}N(CR^{17}) -,
         R¹⁴HNCO-, or
         R14CONH-;
      R^{12} is
         Η,
         Halogen halogen,
         HO,
         R130-,
         R15R16N-,
         C1-C3-alkyl,
         CF,
         R14CO2-,
         R14CO-, or
         R14CONHO;
      R<sup>13</sup> is C1-C3-alkyl;
      R14 is H or C1-C3-alkyl;
```

```
Attorney Docket No.: SYM114 (TI-0029)
                            Pei et al.
Inventors:
                            09/882,843
Serial No.:
                            June 15, 2001
Filing Date:
Page 16
      R15 and R16 are independently
        H,
        C1-C10-alkyl,
        C1-C6-perfluoroalkyl,
        C3-C10, alkenyl, or
        C3-C6-cycloalkyl; or
      R<sup>15</sup> and R<sup>16</sup> taken together can be C3-C6-cycloalkyl;
      R<sup>17</sup> is Cl-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;
      n is 1 to 6;
      m is 0 to 2;
 and pharmaceutically acceptable salts thereof;
       wherein R10 and R11 cannot be both H,
 in combination with a pharmaceutically acceptable carrier.
 Claim 11: (currently amended) The method of claim 10 wherein, in
 the compound of Formula I, one of four the substituents of R1,
 \mathbb{R}^2, \mathbb{R}^3 and \mathbb{R}^4 must be Cl-C3-alkylthic group or Cl-C3-alkoxy group,
 the other substituents are independently H, R^{13}O-, R^{14}S- R^{13}S-,
 halogen, or C1-C3-alkyl; R2 and R3 taken together can be -SCH2S-, -
 SCH<sub>2</sub>O-, or -OCH<sub>2</sub>S-;
 R9 is
       R15R16NCO-,
```

```
Attorney Docket No.: SYM114 (TI-0029)
Inventors: Pei et al.
Serial No.: 09/882,843
Filing Date: June 15, 2001
Page 17

R<sup>15</sup>R<sup>16</sup>NCS-,
R<sup>15</sup>R<sup>16</sup>N(CR<sup>17</sup>)-,
R<sup>17</sup>OCO-, or
R<sup>15</sup>CO-
H;
```

 R^{10} and R^{11} are independently H, H_2N_- , or CH_3CONH_- ; and pharmaceutically acceptable salts thereof.

Claim 12 (canceled)

Claim 13: (currently amended) The method of claim 11 claim 10 wherein the compound of Formula I is selected from the group consisting of

1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-propylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-

Attorney Docket No.: SYM114 (TI-0029) Pei et al. Inventors: 09/882,843 Serial No.: June 15, 2001 Filing Date:

Page 18

4-methyl-3-acetyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-7methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5dihydro-4-methyl-3-ethylcarbamoyl-7-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3propylcarbamoyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-7methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4methyl-3-acetyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3methylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5 -dihydro-4-methyl-3-ethylcarbamoyl-8-methoxy-5H-2.3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino -3,5-dihydro-4methy1-3-acety1-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbomyl-8methoxy-5H-2,3-benzodiazepine, 1-(4-aminophenyl)-7-amino-3,5dihydro-4-methyl-3-ethylcarbomoyl-8-methoxy-5H-2,3-

Attorney Docket No.: SYM114 (TI-0029) Pei et al. Inventors: 09/882,843 Serial No.: June 15, 2001 Filing Date:

Page 19

benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3propylcarbomoyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl) -7-amino-3,5-dihydro-4-methyl-3-butylcarbamnoyl-8methoxy-5H-2,3-benzodiazepine, 1-(4- Aminophenyl)-3,5-dihydro -4-methyl-3-acetyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-methylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5dihydro-4-methyl-3-ethylcarbamoyl-7-methylthio-51H-2,3benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methvl-3-butylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3-acetyl-7-methylthio-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4-methyl-3methylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminopheny1)-8-amino-3,5-dihydro-4- methyl-3-ethylcarbamoyl -7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-3 ,5-dihydro-4-methyl-3-propylcarbamoyl-7-methvlthio-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-8-amino-3,5-dihydro-4methyl-3-butylcarbamoyl-7-methylthio-5H-2,3-benzodiazepine, 1 -(4-Aminophenyl)-3,5-dihydro-4-methyl-3-acetyl-8-methylthio-5H-2,

2024

Attorney Docket No.: SYM114 (TI-0029) Inventors: Pei et al. Serial No.: 09/882,843 Filing Date: June 15, 2001

Page 20

3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3methylcarbamoyl-S-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5H-2,2-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3propylcarbamoyl-8-methylthiio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-3,5-dihydro-4-methyl-3-butylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4methyl-3-acetyl-8-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-methylcarbamoyl-8methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5dihydro-4-methyl-3-ethylcarbamoyl-8-methylthio-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methy1-3propylcarbamoyl-8-methylthio-5H-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-3,5-dihydro-4-methyl-3-butylcarbamoyl-8methylthio-5H-2,3-benzodiazepine.

Claims 14-15 (canceled)

Claim 16: (currently amended) A compound of Formula II:

Attorney Docket No.: SYM114 (TI-0029)

Inventors:

Pei et al.

Serial No.: Filing Date: 09/882,843 June 15, 2001

Page 21

$$R^{3}$$
 R^{4}
 R^{5}
 R^{6}
 R^{7}
 R^{19}
 R^{19}
 R^{21}

wherein

R1 and R4 are independently

н,

HО,

R130-,

R13S-

Halogen halogen,

C1-C3-alkyl,

CF₃,

 $R^{14}CO_2-$,

 $R^{14}O_2C-$

R1ªCO-

R14CONH-,

SYM114 (TI-0029)

Inventors: Serial No.: Pei et al. 09/882,843

Filing Date:

June 15, 2001

Page 22

R14NHCO-,

Attorney Docket No.:

 $R^{14}NHCO_2-$

R14OCONH-,

R14O2S-,

R14O5-,

R¹¹3-, or

R15R16N-; or

 R^{2} is one of H, HO, $R^{13}O$, halogen, C1-C3-alkyl, CF₃, $R^{14}CO_{2}$ -, $R^{14}O_{2}C$ -, $R^{14}CO_{2}$ -, $R^{14}CO_{2}$ -, $R^{14}CO_{2}$ -, $R^{14}CO_{2}$ -, $R^{14}CO_{2}$ -, $R^{14}O_{2}C$ -, $R^{14}O$

 $R^{2} \text{ is one of H, HO, halogen, C1-C3-alkyl, CF}_{3}, R^{14}CO_{2}-, \\ R^{14}O_{2}C-, R^{14}CO-, R^{14}CONH-, R^{14}NHCO-, R^{14}NHCO_{2}, R^{14}OCONH-, R^{14}O_{2}S-, \\ R^{14}OS-\frac{R^{14}S-}{R^{13}S-} \text{ and } R^{15}R^{16}N- \text{ when } R^{3} \text{ is one of H, HO, } R^{13}O, \\ halogen, C1-C3-alkyl, CF}_{3}, R^{14}CO_{2}-, R^{14}O_{2}C-, R^{14}CO-, R^{14}CONH-, \\ R^{14}NHCO-, R^{14}NHCO_{2}, R^{14}OCONH-, R^{14}O_{2}S-, R^{14}OS-\frac{R^{14}S-}{R^{13}S-} \text{ and } R^{15}R^{16}N-; \\ or$

 R^1 and R^2 , or R^2 and R^3 , or R^3 and R^4 taken together can be

-SCH₂S-,

-SCH₂O-,

-OCH2S-,

```
SYM114 (TI-0029)
Attorney Docket No.:
                               Pei et al.
Inventors:
                               09/882,843
Serial No.:
                               June 15, 2001
Filing Date:
Page 23
      -SCH<sub>2</sub>CH<sub>2</sub>S-,
      -SCH<sub>2</sub>CH<sub>2</sub>O-, or
      -OCH2CH2S-; or
      wherein one of four the substituents of R^1, \overline{R}^2, R^2 and R^4.
must be C1-C3-alkoxy or C1-C3-alkylthio group;
      R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently
      Η,
      C1-C6-alkyl,
      C3-C6-alkenyl,
      C3-C6-cycloalkyl,
      phenyl or substituted phenyl, wherein the phenyl is
substituted with one or two substituents, C1-C3-alkyl, halogen,
R^{12}O-, CF_3-, R^{14}O_2S-, R^{14}OS-, R^{14}CO, R^{14}CO_2-, R^{14}O_2C-, R^{14}CONH-, R^{14}NHCO;
or
      R<sup>5</sup> and R<sup>6</sup> taken together can be C3-C6-cycloalkyl;
      R<sup>13</sup> is C1-C3-alkyl;
      R14 is H or C1-C3-alkyl;
      R15 and R16 are independently
         Η,
         C1-C10-alkyl,
         C1-C6-perfluoroalkyl,
         C3-C10-alkenyl, or
```

20028

LICATA & TYRRELL

```
Attorney Docket No.: SYM114 (TI-0029)
Inventors:
                          Pei et al.
                           09/882,843
Serial No.:
Filing Date:
                           June 15, 2001
Page 24
       C3-C6-cycloalkyl; or
     R15 and R16 taken together can be C3-C6-cycloalkyl;
     R18 and R19 are independently
       Η,
       Halogen halogen,
       C1-C3-alkyl,
       R14O-,
       CF_3-, or
       R14CO, -;
R<sup>20</sup> and R<sup>21</sup> are independently
       Ħ,
       R15R16N-,
       R15HNC(NH) - or
       R14CONH-;
and pharmaceutically acceptable salts thereof;
     wherein R20 and R21 cannot both be H.
```

Claim 17: (currently amended) The compound of claim 16 of Formula II wherein one of four the substituents of R2, R2, R3 and R4 must be Cl-C3-alkylthio group or Cl-C3-alkoxy group, the other substituents are independently H, R13O-, R12S-, halogen, or C1-C3alkyl;

Attorney Docket No.: SYM114 (TI-0029)

Inventors: Pei et al.
Serial No.: 09/882,843
Filing Date: June 15, 2001

Page 25

 R^2 and R^3 taken together can be -SCH₂S-, -SCH₂O-, or -OCH₂S-; R^{20} and R^{21} are independently H, H₂N-, or CH₃CONH-; and pharmaceutically acceptable salts thereof.

Claim 18: (previously amended) A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.

Claim 19: (canceled)

Claim 20: (currently amended) The compound of claim 17 claim 16 of Formula II selected from the group consisting of 1-(4-Aminophenyl)-4-methyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-8-amino-4-methyl-7-methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8-methylthio-5H-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7-amino-4-methyl-8-methylthio-5H-2,3-benzodiazepine.

Claim 21: (previously amended) A composition comprising the

Attorney Docket No.:

SYM114 (TI-0029)

Inventors: Serial No.: Filing Date:

09/882,843 June 15, 2001

Pei et al.

Page 26

compound of claim 20 and a pharmaceutically acceptable carrier.

Claim 22: (canceled)

Claim 23: (previously amended) A composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

Claim 24: (canceled)

Claim 25: (currently amended) A method for treating a patient having a disorder associated with excessive activation of the amino-3-hydroxy-5-methyl-4-isooxazoleproprionic acid (AMPA) subtype of the ionotropic excitatory amino acid (EAA) receptors suffering from ischemia, epilepsy or stroke, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the disorder ischemia, epilepsy or stroke, a compound of Formula II:

Attorney Docket No.:

SYM114 (TI-0029)

Inventors: Serial No.: Pei et al.

Filing Date:

09/882,843 June 15, 2001

Page 27

wherein

R1 and R4 are independently

H,

HO,

R13O-,

R13S-

Halogen halogen,

C1-C3-alkyl,

CF3,

 $R^{14}CO_2-$

 $R^{19}O_2C_7$

R14CO-

R14CONH-,

-SCH2CH2S-,

```
SYM114 (TI-0029)
Attorney Docket No.:
Inventors:
                                     Pei et al.
                                     09/882,843
Serial No.:
                                     June 15, 2001
Filing Date:
Page 28
  R14NHCO-,
  R^{14}NHCO_2-,
  R14OCONH-,
  R140,S-,
  R1405~,
  R148-, or
  R^{15}R^{16}N-; or
  R^2 is one of H, HO, R^{13}O, halogen, C1-C3-alkyl, CF_3, R^{14}CO_2-,
R^{14}O_{2}C_{-}, R^{14}CO_{-}, R^{14}CONH_{-}, R^{14}NHCO_{-}, R^{14}NHCO_{2}, R^{14}OCONH_{-}, R^{14}O_{2}S_{-},
R^{14}OS - R^{14}S - and R^{15}R^{16}N - when R^3 is one of HO, halogen, C1-C3-
alkyl, CF_3, R^{14}CO_2-, R^{14}O_2C-, R^{14}CO-, R^{14}CONH-, R^{14}NHCO-, R^{14}NHCO_2,
R^{14}OCONH-, R^{14}O_2S-, R^{14}OS-, R^{14}S- R^{13}S- and R^{15}R^{16}N-; or
  R<sup>2</sup> is one of H, HO, halogen, C1-C3-alkyl, CF<sub>1</sub>, R<sup>14</sup>CO<sub>2</sub>-,
R14O2C-, R14CO-, R14CONH-, R14NHCO-, R14NHCO2, R14OCONH-, R14O2S-,
R^{14}OS - \frac{1}{r-R^{14}S} and R^{15}R^{16}N when R^3 is one of H, HO, R^{13}O, halogen,
C1-C3-alkyl, CF<sub>3</sub>, R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>CO-, R<sup>14</sup>CO-, R<sup>14</sup>CONH-, R<sup>14</sup>NHCO-,
R^{14}NHCO_2, R^{14}OCONH-, R^{14}O_2S-, R^{14}OS-\frac{R^{14}S-}{R^{13}S-} and R^{15}R^{16}N-; or
  R1 and R2, or R2 and R3, or R3 and R4 taken together can be
   -SCH<sub>2</sub>S-,
   -SCH<sub>2</sub>O-,
   -OCH<sub>2</sub>S-,
```

```
Attorney Docket No.: SYM114 (TI-0029)
                            Pei et al.
Inventors:
                             09/882,843
Serial No.:
                            June 15, 2001
Filing Date:
Page 29
 -SCH<sub>2</sub>CH<sub>2</sub>O-, or
 -OCH,CH,S-; or
wherein one of four the substituents of R^1, -R^2, R^3 and R^4 must be
C1-C3-alkoxy or C1-C3-alkylthio group;
 R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently
 Η,
 C1-C6-alkyl,
 C3-C6-alkenyl,
 C3-C6-cycloalkyl,
 phenyl or substituted phenyl, wherein the phenyl is substituted
with one or two substituents, C1-C3-alkyl, halogen, R13O-, CF3-,
R^{14}O_2S-, R^{14}OS-, R^{14}CO, R^{14}CO_2-, R^{14}O_2C-, R^{14}CONH-, R^{14}NHCO; or
   R<sup>5</sup> and R<sup>6</sup> taken together can be C3-C6-cycloalkyl;
   R<sup>13</sup> is C1-C3-alkyl;
   R14 is H or C1-C3-alkyl;
   R15 and R16 are independently
   Η,
   C1-C10-alkyl,
  C1-C6-perfluoroalkyl,
  C3-C10-alkenyl, or
  C3-C6-cycloalkyl; or
  R15 and R16 taken together can be C3-C6-cycloalkyl;
```

```
Attorney Docket No.: SYM114 (TI-0029)
                           Pei et al.
Inventors:
                           09/882,843
Serial No.:
                           June 15, 2001
Filing Date:
Page 30
 R18 and R19 are independently
 H,
 Halogen halogen,
 C1-C3-alkyl,
 R140-,
 CF3, or
 R14CO2-;
R<sup>20</sup> and R<sup>21</sup> are independently
 Η,
 R^{15}R^{16}N-,
 R15HNC(NH) - or
  R14CONH-;
and pharmaceutically acceptable salts thereof;
  wherein R20 and R21 cannot both be H.
in combination with a pharmaceutically acceptable carrier.
```

Claim 26: (currently amended) The method of claim 25 wherein, in the compound of Formula II wherein one of four the substituents of R¹, R², R³ and R⁴ must be Cl-C3-alkylthio group or Cl-C3-alkoxy group, the other substituents are independently H, R¹³O-, R¹³S-, halogen, or Cl-C3-alkyl;
R₂ and R₃ taken together can be -SCH₂S-, -SCH₂O-, or -OCH₂S-;

Attorney Docket No.:

SYM114 (TI-0029)

Inventors: Serial No.: Filing Date: Pei et al. 09/882,843 June 15, 2001

Page 31

R²⁰ and R²¹ are independently H, H₂N-, or CH₃CONH-; and pharmaceutically acceptable salts thereof.

Claim 27 (canceled)

Claim 28: (currently amended) The method of claim 26 claim 25 wherein the compound of Formula II is selected from the group consisting of 1-(4-Aminophenyl)-4-methyl-7-methoxy-5H-2,3benzodiazepine, 1-(4-Aminophenyl)-8amino-4-methyl-7-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-7-amino-4-methyl-8-methoxy-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-7-methylthio-5H-2,3-benzodiazepine,1-(4-Aminophenyl)-8-amino-4-methyl-7methylthio-5H-2,3-benzodiazepine, 1-(4-Aminophenyl)-4-methyl-8methylthio-5H-2,3-benzodiazepine, and 1-(4-Aminophenyl)-7amino-4-methyl-8-methylthio-5H-2,3-benzodiazepine.

Claims 29-30 (canceled)